T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$2.03B |
| 2 |
Rockwell Automation
ROK
|
+$1.44B |
| 3 |
Autodesk
ADSK
|
+$1.15B |
| 4 |
Citigroup
C
|
+$975M |
| 5 |
ConocoPhillips
COP
|
+$967M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.59B |
| 2 |
GE Aerospace
GE
|
+$1.78B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.38B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 5 |
Philip Morris
PM
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.21% |
| 2 | Healthcare | 15.42% |
| 3 | Financials | 10.99% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FRGE
2826
DELISTED
Forge Global Holdings
FRGE
| $66K | ﹤0.01% |
2,246
+511
| +29% | +$16K |
|
2827
Vanda Pharmaceuticals
VNDA
$307M
| $66K | ﹤0.01% |
15,824
+2,425
| +18% | +$9.71K |
|
2828
Alto Ingredients
ALTO
$327M
| $65K | ﹤0.01% |
29,600
| – | – |
|
|
OPI
2829
DELISTED
Office Properties Income Trust
OPI
| $65K | ﹤0.01% |
31,712
| – | – |
|
2830
iQIYI
IQ
$1.3B
| $64K | ﹤0.01% |
14,900
-6,920
| -32% | -$26.6K |
|
2831
Zevra Therapeutics
ZVRA
$671M
| $64K | ﹤0.01% |
+11,011
| New | +$67.7K |
|
|
TWKS
2832
DELISTED
Thoughtworks Holding, Inc. Common Stock
TWKS
| $64K | ﹤0.01% |
25,182
+2,147
| +9% | +$8.23K |
|
2833
CorMedix
CRMD
$631M
| $63K | ﹤0.01% |
14,635
+2,562
| +21% | +$8.88K |
|
2834
Holley
HLLY
$364M
| $63K | ﹤0.01% |
14,047
+1,771
| +14% | +$8.09K |
|
|
CONN
2835
DELISTED
Conn's Inc.
CONN
| $63K | ﹤0.01% |
18,700
| – | – |
|
2836
Dare Bioscience
DARE
$20.2M
| $62K | ﹤0.01% |
10,492
| – | – |
|
|
GAN
2837
DELISTED
GAN Ltd
GAN
| $62K | ﹤0.01% |
48,300
| – | – |
|
|
ONL
2838
Orion Office REIT
ONL
$160M
| $62K | ﹤0.01% |
17,574
+3,161
| +22% | +$14.2K |
|
|
ITI
2839
DELISTED
Iteris, Inc.
ITI
| $62K | ﹤0.01% |
12,454
+2,067
| +20% | +$10.2K |
|
2840
Aemetis
AMTX
$126M
| $61K | ﹤0.01% |
10,100
| – | – |
|
2841
Emergent Biosolutions
EBS
$239M
| $61K | ﹤0.01% |
23,943
+4,409
| +23% | +$9.94K |
|
|
PSTX
2842
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $61K | ﹤0.01% |
18,817
+2,280
| +14% | +$7.6K |
|
|
OLPX
2843
DELISTED
Olaplex Holdings
OLPX
| $60K | ﹤0.01% |
30,957
+6,614
| +27% | +$13.8K |
|
2844
Quantum Corp
QMCO
$935M
| $60K | ﹤0.01% |
5,030
-3,730
| -43% | -$33.5K |
|
2845
Cipher Digital
CIFR
$6.91B
| $59K | ﹤0.01% |
+11,308
| New | +$39.2K |
|
2846
Destination XL Group
DXLG
$33.2M
| $59K | ﹤0.01% |
16,314
+2,719
| +20% | +$10.7K |
|
2847
BRC Inc
BRCC
$211M
| $57K | ﹤0.01% |
12,921
+1,666
| +15% | +$6.91K |
|
2848
Full House Resorts
FLL
$85M
| $57K | ﹤0.01% |
+10,167
| New | +$50.3K |
|
|
QIPT
2849
DELISTED
Quipt Home Medical
QIPT
| $57K | ﹤0.01% |
12,829
+2,640
| +26% | +$11.9K |
|
|
ENZ
2850
DELISTED
Enzo Biochem, Inc.
ENZ
| $57K | ﹤0.01% |
44,800
| – | – |
|
Similar funds
T. Rowe Price Associates's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Associates held 3,021 positions worth $816B, up 9.6% from $744B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2024 filing shows 108 new, 1,941 increased, 738 reduced and 64 closed positions. Its largest new stake was GE Vernova: 2,687,194 shares worth $367M. The largest sale was NVIDIA, an estimated $2.59B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2024 buy was GE Vernova: 2,687,194 shares worth $367M.
- T. Rowe Price Associates added most to Fortinet in Q1 2024, an estimated $2.03B increase.
- T. Rowe Price Associates's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $2.59B.
- T. Rowe Price Associates fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $621M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $816B portfolio in Q1 2024.
- T. Rowe Price Associates opened 108 new positions and closed 64 in Q1 2024.
- T. Rowe Price Associates's portfolio value rose 9.6% quarter-over-quarter to $816B.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.